Mackenzie Financial »

Black Diamond Therapeutics shares owned by Mackenzie Financial

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Mackenzie Financial from 13F filings

Historical chart of Mackenzie Financial investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Mackenzie Financial consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Mackenzie Financial

Quarter filed Position value Share count Share price at filing
2025-12-31 $876k 353k 2.49

More positions owned by Mackenzie Financial

Rbc Cad (RY)
Microsoft Corporation (MSFT)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Toronto Dominion Bk Ont Com New (TD)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Alphabet Cap Stk Cl A (GOOGL)
Shopify Cl A Sub Vtg Shs (SHOP)
Amazon (AMZN)
Agnico (AEM)
Bank Of Montreal Cadcom (BMO)
Canadian Pacific Kansas City (CP)
Brookfield Corp Cl A Ltd Vt Sh (BN)
Canadian Natural Resources (CNQ)
Manulife Finl Corp (MFC)

View all positions for Mackenzie Financial

Top funds holding Black Diamond Therapeutics

T. Rowe Price Investment Management
NEA Management Company
Vanguard Group
Acadian Asset Management
Marshall Wace
Siren
Arrowstreet Capital, Limited Partnership
Jane Street
Renaissance Technologies
BlackRock
Vestal Point Capital
Dimensional Fund Advisors
Millennium Management
Connor, Clark & Lunn Investment Management
AWM Investment Company

View all funds holding Black Diamond Therapeutics